Cord blood Platelet Rich Plasma derivatives for clinical applications in non-transfusion medicine

dc.contributor.author
Samarkanova, Dinara
dc.contributor.author
Cox, Steven
dc.contributor.author
Hernández, Diana
dc.contributor.author
Rodriguez Gómez, Luciano
dc.contributor.author
Casaroli Marano, Ricardo Pedro
dc.contributor.author
Madrigal, Alejandro
dc.contributor.author
Querol Giner, Sergi
dc.date.issued
2021-04-22T10:16:53Z
dc.date.issued
2021-04-22T10:16:53Z
dc.date.issued
2020-05-27
dc.date.issued
2021-04-22T10:16:53Z
dc.identifier
1664-3224
dc.identifier
https://hdl.handle.net/2445/176622
dc.identifier
710209
dc.identifier
32536916
dc.description.abstract
Cord blood platelet rich plasma (CB-PRP) derivatives have been investigated as potential therapeutic agents for the treatment of diverse conditions including ocular surface disease and skin ulcers. We have developed processes for the formulation of several CB-PRP preparations, which have different composition and attributes. Here we describe the molecular characteristics of these preparations and we make recommendations as to their most appropriate clinical application based on functional and immunomodulatory profiles. We show that incubation of adult peripheral blood mononuclear cells (PBMCs) with all three preparations dramatically reduced the production of INFγ and the expression of NKG2D and CD107a in NK, NKT, and T cells thus diminishing their activation, we propose that the likely mechanism is the high levels of soluble NKG2D ligands present in plasma. Of the three preparations we investigated, CB platelet lysate (PL) and platelet releaseate (PR) have higher concentrations of trophic and pro-angiogenic factors, CB platelet poor plasma (PPP) has the lowest concentration of all analytes measured. Based on these finding we propose that CB-PR is the most suitable raw material for skin wound patches, while CB-PL and PPP can be used to prepare eye drops for severe ocular surface pathologies and inflammatory conditions such as corneal ulcers or severe dry eye disease, respectively.
dc.format
14 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Frontiers Media
dc.relation
Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2020.00942
dc.relation
Frontiers in Immunology, 2020, vol. 11, p. 942
dc.relation
https://doi.org/10.3389/fimmu.2020.00942
dc.rights
cc-by (c) Samarkanova, Dinara et al., 2020
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
dc.subject
Sang fetal
dc.subject
Úlceres
dc.subject
Plaquetes sanguínies
dc.subject
Fetal blood
dc.subject
Ulcers
dc.subject
Blood platelets
dc.title
Cord blood Platelet Rich Plasma derivatives for clinical applications in non-transfusion medicine
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)